US Microscopy Market

The US microscopy market is estimated to reach USD 3.25 billion by 2031 from USD 2.35 billion in 2025, at a CAGR of 5.5% during the forecast period.

Technological innovations like AI/ML integration, digital/3D confocal microscopy, and cryo-EM are propelling the US microscopy market to new heights. These advancements have led to major breakthroughs in resolution, automation of analysis, and overall efficiency in life sciences and semiconductor R&D. Increased investment in R&D, driven by NIH's annual funding of over $42.5 billion, NSF grants, and expenditures from pharma and biotech sectors, has significantly boosted demand for nanoscale imaging in fields such as nanotechnology, regenerative medicine, precision oncology, and structural biology. Additionally, the USD 52 billion investment from the CHIPS Act in semiconductor metrology and defect inspection at domestic fabs like Intel and GlobalFoundries aims to reduce supply risks from Asia, as the industry moves toward sub-2nm node miniaturization.

To know about the assumptions considered for the study download the pdf brochure

The growth of biotech hubs in Boston and San Diego is driving the demand for high-throughput protein and pathology imaging used in drug discovery and diagnostics. The DOE/NIST-supported programs are fostering the adoption of SPM, SEM, and TEM in quantum materials, advanced composites, and clean energy applications. As a result, the microscopy market is expected to grow at a rate of more than 7% annually until 2030.
Currently, leading companies in the microscopy market include Carl Zeiss AG (Germany), Thermo Fisher Scientific (US), EVIDENT (Japan), Danaher Corporation (US), Nikon Corporation (Japan), JEOL Ltd. (Japan), Oxford Instruments plc (UK), Hitachi High–Tech Corporation (Japan), Keyence Corporation (Japan), Shimadzu Corporation (Japan), Euromex Microscopen bv (Netherlands), Bruker Corporation (US), and Helmut Hund GmbH (Germany).

Carl Zeiss AG (Germany):

Carl Zeiss AG (ZEISS), headquartered in Oberkochen, Germany, is a leading global company in optics and photonics innovation, operating through four business groups: Precision Technology, Medical Technology, Consumer Markets, and Semiconductor Manufacturing Technology. As part of its Precision Technology division, the company's Microscopy division provides access to advanced microscopy solutions for life sciences research, materials science research, and quality analysis and testing.

Along with holding a dominant market share in the US through its diverse range of microscopy systems such as optical microscopes, electron microscopes, and multi-modal microscopes based on optical and electron technologies for research and production, ZEISS is establishing itself in the US microscopy market through effective strategic placement by its North America Headquarters in Thornwood, NY. It is also developing AI-driven platform technology like ZEN Intellesis and introducing lattice SIM2 technology for semiconductor metrology for Intel and TSMC, as well as cryo-EM and AXIOSCAN slidescan for NIH-funded biotech companies based in Boston and San Diego. Key strategic areas include capacity expansion compliant with the CHIPS Act for sub-2nm inspection technology, cloud-based digital pathology for medical diagnostics, and environment-friendly LED and eco-optics for sustainability.

Thermo Fisher Scientific (US):

Thermo Fisher Scientific Inc., a global leader in life sciences and analytical instruments with headquarters in Waltham, Massachusetts, has four operating segments: Life Sciences Solutions, Analytical Instruments, including microscopy, Specialty Diagnostics, and Laboratory Products/Services.

The microscopy portfolio, which includes the brands Thermo Scientific and FEI, maintains a strong presence in the US market for SEM, TEM, FIB-SEM, and Dual-Beam systems serving semiconductor, life sciences, and materials research. Strategic decisions within the US microscopy market include CHIPS Act-aligned innovations such as the Scios 3 FIB-SEM, set to launch in 2025 for nanoscale lamella prep and automation in Intel and GlobalFoundries fabs, and the broadly available Talos 12 TEM for biotech and protein Cryo-EM. Other sustainability targets include achieving 100% renewable energy at US manufacturing sites by 2026, integrating AI workflows, and expanding semiconductor metrology toward less than 2nm nodes.

Danaher Corporation (US):

Danaher Corporation is based in Washington, DC, and is a leading global science and technology company. The company operates through three segments: Biotechnology, Life Sciences, and Diagnostics. It employs 63,000 people to serve 63,000 clients in the pharmaceutical, biotechnology, and healthcare industries. Its microscopy division, mainly from Leica Microsystems, is known for advanced confocal and super-resolution, stereo systems used in life sciences research, semiconductor inspection, and clinical pathology.

Danaher's strategy in the US microscopy market is to leverage AI-powered imaging platforms like Leica THUNDER for live-cell analysis at NIH-funded research sites in Boston and San Diego. It also focuses on providing semiconductor metrology solutions in line with the CHIPS Act for fabrication plants such as those operated by Intel and GlobalFoundries. Danaher highlights its recurring service revenue, which account for over 80%, along with strategic acquisitions to enhance its cryo-EM and SEM capabilities. Additionally, by promoting integrated workflows that lower the risk of oncology trial failures, Danaher aims to compete with companies like ZEISS and Thermo Fisher in fields like precision diagnostics and genomics R&D, utilizing their R&D facilities.

Related Reports:

US Microscopy Market by Product [Optical Microscope: Stereo, Digital; Electron Microscope: SEM, TEM; AFM, STM], Application (Pharma Mfg, Pathology, Drug Discovery, Toxicology), End User (Pharma-Biopharma, F&B, Academia, Semiconductor) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]